Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 4/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.36 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824874 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL30381659 | 1.00 | CHRM2 (0.50) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2299743 | 0.91 | CHRM2 (0.49) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL178638 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL2267993 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL23807724 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL402018 | 0.84 | CHRM2 (0.59) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL22569401 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL21219895 | 0.84 | CHRM2 (0.64) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 | |
| SCHEMBL24762766 | 0.84 | CHRM2 (0.59) | CHRM2CHRM1CHRM3USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4539849-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| WO-2023244764-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | C4 THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| EP-4192458-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 Therapeutics, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032026-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | C4 THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250121070-A1 | COMPOUNDS FOR THE TARGETED DEGRADATION OF SMARCA2 | SMARCA2, SMARCE1, SMARCA1 | CHRM2 2735/4885CHRM1 3008/4885CHRM3 4156/4885 |
| US-20230233692-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF RET | RET, HRAS, RBX1 | CHRM2 4796/4885CHRM1 4808/4885CHRM3 4749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.